PIONEERING PRECISION IN
|
|
|
|
At Photonic Pharma LLC, we focus on the early phase of drug development - Lead Discovery - using a game-changing technology platform that combines breakthroughs in fluorescent biosensor engineering and fluorescence lifetime detection in living cells. Thus we achieve a dramatic 30-fold increase in the precision of high-throughput screening of small-molecule libraries, with the potential to transform the productivity of pharmaceutical development.
We partner with industrial and academic collaborators, applying our proprietary advancements in structure-based drug-screening technology, to discover novel small-molecule effectors of therapeutically important protein targets. We have assembled a robust and highly integrated network of techniques, concepts, facilities and collaborators to address a wide range of therapeutic goals. |
PHOTONIC PHARMA NEWS:
October 16, 2019
Photonic Pharma LLC is pleased to announce the fifth anniversary of our founding as we begin our sixth year of business. Photonic sends thanks to all those who made this possible.
October 16, 2019
Photonic Pharma LLC is pleased to announce the fifth anniversary of our founding as we begin our sixth year of business. Photonic sends thanks to all those who made this possible.
September 16, 2019
Photonic Pharma LLC is pleased to announce that Bristol-Myers Squibb (NYSE: BMY), has signed a 1-year extension of the research term of a collaboration and license agreement with Photonic Pharma through January 2, 2021.
Photonic Pharma LLC is pleased to announce that Bristol-Myers Squibb (NYSE: BMY), has signed a 1-year extension of the research term of a collaboration and license agreement with Photonic Pharma through January 2, 2021.
September 15, 2019
Photonic Pharma LLC is pleased to announce that it was awarded an SBIR Phase I grant of $594K from the National Institute on Aging related to new therapeutic avenues for the treatment of Alzheimer's disease.
For the full story and other news, please visit the News tab.
Photonic Pharma LLC is pleased to announce that it was awarded an SBIR Phase I grant of $594K from the National Institute on Aging related to new therapeutic avenues for the treatment of Alzheimer's disease.
For the full story and other news, please visit the News tab.